Odyssey Therapeutics (ODTX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, leveraging expertise in immunobiology, medicinal and computational chemistry, and protein biochemistry.

• Lead programs include OD-001 (RIPK2 inhibitor for ulcerative colitis) and OD-002 (SLC15A4 inhibitor for interferonopathies and B cell-mediated diseases), with additional preclinical assets targeting key immune pathways.

• Business model centers on internal drug discovery, global clinical development, and potential collaborations for select programs.

Financial performance and metrics

• Reported net losses of $148.6 million in 2025 and $129.3 million in 2024, with an accumulated deficit of $568.1 million as of December 31, 2025.

• Collaboration revenue was $3.0 million in 2025, down from $4.5 million in 2024, primarily from agreements with Pfizer and Janssen.

• Cash, cash equivalents, and marketable securities totaled $216.6 million as of December 31, 2025.

• Pro forma cash after IPO and concurrent private placement expected to be $445.0 million.

Use of proceeds and capital allocation

• Net proceeds of approximately $205.2 million from the IPO and $23.3 million from a concurrent private placement are expected.

• Proceeds will fund OD-001 through phase 2a and 2b trials, advance OD-002 through IND-enabling and phase 1/2a studies, support additional pipeline development, and for general corporate purposes.

• Expected to fund operations into the second half of 2028.